Every 8-K that electroCore, Inc. (ECOR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ECOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ECOR filings page.
electroCore, Inc. (ECOR) announced a leadership and governance overhaul centered on a new co-Chief Executive Officer structure. On September 8, 2026, the Board appointed Joshua S. Lev and Michael Fox as co-CEOs and Presidents, while Lev continues as Chief Financial Officer and Fox as Chief Operating Officer. Both were also added as Class III directors, expanding the Board from six to eight members, and each received 55,000 RSUs that vest over three years, along with salary increases to $540,000 and target cash bonuses set at 50% of base salary.
The Board approved an Amended and Restated Executive Severance Policy, revising “Base Compensation,” raising certain Change in Control ownership thresholds to 50%, unifying normal severance terms and increasing the CEO Change in Control severance formula to 1.5x base compensation plus target bonus. New Third Amended and Restated Bylaws significantly tighten advance notice and universal proxy (Rule 14a-19) compliance requirements, extend them to special meetings and expressly authorize co-CEOs. At the annual meeting, all three Class II director nominees were elected and shareholders approved say‑on‑pay and ratified CBIZ CPAs as auditor.
electroCore, Inc. reported second-quarter 2026 net sales of $9.5 million, up approximately 28% year-over-year, led by U.S. prescription sales to the Veterans Affairs system and general wellness products. Quell revenue reached $1.3 million, growing about 700% versus 2025, while Truvaga revenue was $1.3 million, up 27% year-over-year but down 17% sequentially as marketing spend was reduced.
Gross profit was $8.2 million with gross margin of 86.5%. Operating expenses rose to $10.9 million, reflecting higher sales and marketing and R&D, partly offset by lower general and administrative costs. GAAP net loss narrowed to $3.1 million, or $0.33 per share, and adjusted EBITDA net loss improved to $1.8 million. Cash, cash equivalents and marketable securities totaled about $10.0 million at June 30, 2026, with the balance sheet showing a stockholders’ deficit of $2.8 million.
The company is restructuring its commercial organization, expanding sales regions, adding 1099 representatives, revising incentives, and consolidating federal contracting through Lovell Government Services to lower fees and improve scalability. Management raised full-year 2026 revenue guidance to greater than 30% growth over 2025 and expects to achieve positive adjusted EBITDA in the third quarter of 2027.
electroCore, Inc. reported strong first quarter 2026 growth, with net sales of $9.6 million, up about 43% from $6.7 million a year earlier, led by VA prescription gammaCore, Quell Fibromyalgia, and Truvaga wellness products. Gross margin expanded to 87%, lifting gross profit to $8.4 million.
The company still posted a GAAP net loss of $5.3 million, or $0.59 per share, reflecting higher operating expenses, including $1.9 million of one-time leadership transition costs and legal fees. Adjusted EBITDA net loss improved to $2.3 million, and management reaffirmed full-year 2026 revenue growth guidance of about 30% over 2025.
electroCore, Inc. reported strong top-line growth for 2025 while remaining loss-making and announced key leadership changes. Net sales for the year ended December 31, 2025 rose to $32.0 million, up about 27% from 2024, driven by 25% growth in U.S. prescription revenue and a 97% increase in general wellness sales. Gross profit increased to $27.8 million with gross margin improving to 87% from 85%.
Operating expenses rose to $40.9 million, reflecting higher sales and marketing and additional legal, IT, and bad debt costs. GAAP net loss widened to $14.0 million, or $1.65 per share, while adjusted EBITDA net loss improved slightly to $8.7 million. Total cash, cash equivalents, and marketable securities were $11.6 million at year-end and stockholders’ equity showed a deficit of $1.7 million. For 2026, the company guides to roughly 30% annual revenue growth. CEO Dan Goldberger will retire effective April 1, 2026, with CFO Joshua Lev becoming interim President and Michael Fox joining as Chief Operating Officer.
electroCore, Inc. reported that it has issued a press release providing a business update, including select unaudited preliminary financial guidance for the fourth quarter and full year ended December 31, 2025. This information is being shared with the market through a press release and an accompanying investor presentation.
The company’s executive officers plan to use an investor presentation, filed as an exhibit, in upcoming meetings with investors and analysts. The preliminary figures are based on management estimates and have not been audited or reviewed by the company’s independent registered public accounting firm, so they may change and any changes could be material. The company emphasizes that these disclosures are being furnished, not filed, which limits certain legal liabilities and keeps the information from automatically becoming part of other SEC filings unless specifically incorporated by reference.
electroCore, Inc. furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025 and providing updated guidance for the fourth quarter and full year 2025.
The press release is attached as Exhibit 99.1. The company notes that, except for information relating to Adjusted EBITDA net loss from operations and its reconciliation to GAAP, the information in Items 2.02 and 9.01, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
electroCore, Inc. entered into private securities purchase agreements with institutional and accredited investors, issuing 360,737 shares of common stock at $5.145 per share.
The shares were used to satisfy outstanding legal fee obligations, so the company received no cash. The unregistered shares were issued in reliance on Section 4(a)(2) and Regulation D, and electroCore agreed to file a registration statement to cover their resale within 90 days after the October 2, 2025 closing.
electroCore, Inc. reported several corporate governance updates and voting results from its recent annual meeting. The Board appointed Elena Bonfiglioli, a senior healthcare and life sciences executive at Microsoft, as a new Class II director and expanded the Board from seven to eight members. She will receive the company’s standard non-employee director pay and an inaugural equity award.
The Board also named Thomas J. Errico, M.D. as chairman, succeeding F. Peter Cuneo, who retired and did not stand for re-election, with no disagreements cited regarding company matters. Director James C. Theofilos joined the Audit Committee.
Stockholders considered four proposals. An amendment to declassify the Board failed because it did not reach the required two-thirds of outstanding shares, despite 94.62% of votes cast supporting it. Three Class I directors were elected for terms expiring at the 2028 annual meeting, the appointment of CBIZ CPAs P.C. as independent auditor for 2025 was ratified, and named executive officer compensation was approved in a non-binding advisory vote.